Lung Cancer Clinical Trials

Showing 601-620 of 3,692 trials

Holistic Acupuncture for Patients With Chemotherapy Induced Nausea

NCT07201194

The study explores whether acupuncture as a supplement to conventional antiemetic medicine is superior in reducing the level of chemotherapy induced nausea compared to conventional anitemetic medicine alone. A total of 90 patients experiencing chemotherapy induced nausea will be allocated 1:1 to either acupuncture and antiemetic medicine or antiemetic medicine alone. The level of nausea and other cancer related symptoms will be assessed at baseline and 8 and 22 days after enrollment

Breast CancerProstate CancerLung Cancer+3 more

Vejle Hospital90 participantsStarted Nov 2025

Vejle, Denmark

RECRUITINGPhase 1/2

Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC

NCT07136285

Oncolytic virus product named Olvi-Vec combined with Platinum plus Etoposide in patients with late phase SCLC

SCLC, Extensive Stage

Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.27 participantsStarted Jul 2023

Hangzhou, China • Shanghai, China

Holistic Acupuncture for Patients With Chemotherapy Induced Nausea

Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC

Related Searches

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers

Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases

RAPART in Locally Advanced Non-small Cell Lung Cancer Patients

Accuracy Between Transthoracal Needle Aspiration (TTNA) Techniques in Suspected Lung Cancer Patients

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer

Adjuvant Chemotherapy for High-Risk Pathologic Stage I Non-Squamous NSCLC

A Study of YL202 in Selected Patients With Advanced Solid Tumors

QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Clinical Trial of TB511 in Advanced Solid Tumors

Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

A Study of GV20-0251 in Advanced or Refractory Solid Tumors

TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC

Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study